Business
Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in one-on-one meetings with investors at the Jefferies Global Healthcare Conference, being held on November 17-20, 2025 in London, United Kingdom.
About this update from Cytosorbents Corporation
[{"type":"text","content":"PRINCETON, N.J., Nov. 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in one-on-one meetings with investors at the Jefferies Global Healthcare Conference, being held on November 17-20, 2025 in London, United Kingdom.","length":430,"tagName":"p"},{"type":"image","alt":"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents’ flagship product, CytoSorb(R), is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is seeking U.S. FDA and Health Canada marketing approval of DrugSorb™-ATR for antithrombotic drug removal during cardiothoracic surgery. (PRNewsfoto/CytoSorbents Corporation) (PRNewsfoto/CytoSorbents Corporation)","displaySize":"","headline":null,"caption":"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents’ flagship product, CytoSorb(R), is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is seeking U.S. FDA and Health Canada marketing approval of DrugSorb™-ATR for antithrombotic drug removal during cardiothoracic surgery. (PRNewsfoto/CytoSorbents Corporation) (PRNewsfoto/CytoSorbents Corporation)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":185,"url":"https://media.zenfs.com/en/prnewswire.com/60064ee123b2486ff06bf22679aad801"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Vyx_W5YQZ5KQRkzzHXw_Kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMyNjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/60064ee123b2486ff06bf22679aad801","width":400,"height":185}},"href":"https://mma.prnewswire.com/media/2754298/CytoSorbents_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Presentation Details:Date: Tuesday, November 18, 2025Time: 12.30 PM GMT / 7:30 AM ETLive webcast link: Jefferies – CytoSorbents Presentation","length":143,"tagName":"p"},{"type":"text","content":"Live webcast of the presentation will...